[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results

Moderna (MRNA) shares more than doubled on Wednesday morning after the biotech giant posted promising late-stage clinical trial data for its mRNA-based cancer vaccine. In its press release, Moderna said its investigational treatment, intismeran autogene, developed with Merck (MRK), succeeded in the landmark INTerpath-001 Phase 3 study involving 1,137 high-risk melanoma patients.

Following the meteoric run on Aug. 19, Moderna stock is trading at nearly 5x its price at the start of this year.

Fundamentals

See More
  • Market Capitalization, $K 25,135,898
  • Shares Outstanding, K 399,236
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,320 M
  • EBITDA $ -3,172 M
  • 60-Month Beta 0.91
  • Price/Sales 13.24
  • Price/Cash Flow N/A
  • Price/Book 3.81

Options Overview Details

View History
  • Implied Volatility 140.04% (+74.36%)
  • Historical Volatility 298.71%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 140.04% on 08/19/26
  • IV Low 55.61% on 08/20/25
  • Expected Move (DTE 2) 23.80 (13.65%)
  • Put/Call Vol Ratio 2.16
  • Today's Volume 622,861
  • Volume Avg (30-Day) 63,493
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 631,489
  • Open Int (30-Day) 593,857
  • Expected Range 150.58 to 198.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.47
  • Number of Estimates 8
  • High Estimate $-0.80
  • Low Estimate $-3.32
  • Prior Year $-0.51
  • Growth Rate Est. (year over year) -188.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.66 +231.14%
on 08/03/26
176.66 -1.29%
on 08/19/26
+112.56 (+182.08%)
since 07/17/26
3-Month
43.90 +297.22%
on 06/02/26
176.66 -1.29%
on 08/19/26
+128.66 (+281.41%)
since 05/19/26
52-Week
22.28 +682.68%
on 11/21/25
176.66 -1.29%
on 08/19/26
+146.47 (+524.79%)
since 08/19/25

Most Recent Stories

More News
US stocks halt their slide after the Treasury Department moves to ease pressure from the bond market

U.S. stocks rose after the Treasury Department made a move to ease pressure emanating from the bond market

NVDA : 217.56 (-0.99%)
AVGO : 362.48 (-4.61%)
$SPX : 7,707.98 (+0.21%)
EL : 98.01 (+16.30%)
MU : 937.10 (-0.39%)
$IUXX : 29,426.02 (-0.22%)
TOL : 148.58 (+4.00%)
LOW : 220.00 (+2.02%)
INTC : 92.80 (-4.02%)
$DOWI : 53,463.05 (+0.22%)
MRNA : 174.38 (+176.97%)
MRVL : 237.27 (+9.85%)
Stocks Finish Mixed as Bond Yields Fall and Chipmakers Slide

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.21% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.22%....

MSTR : 104.25 (+12.68%)
HL : 20.54 (+14.43%)
SNDK : 1,568.87 (-3.50%)
CDE : 20.93 (+13.07%)
GLXY : 21.90 (+7.20%)
TRI : 104.95 (+4.02%)
COIN : 160.20 (+9.55%)
STX : 832.56 (-7.87%)
WDC : 462.09 (-6.87%)
AMD : 466.42 (-3.71%)
CMC : 68.16 (-3.97%)
SCCO : 194.68 (+3.66%)
Why Is Moderna (MRNA) Stock Rocketing Higher Today

Why Is Moderna (MRNA) Stock Rocketing Higher Today

MRNA : 174.38 (+176.97%)
This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results

Moderna stock rips higher on a major cancer breakthrough. The announcement led William Blair to upgrade MRNA shares to "Outperform."

MRK : 152.20 (+12.60%)
MRNA : 174.38 (+176.97%)
Stocks Supported by Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) is up by +0.58% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.07%. E-mini S&P futures (ESU26...

MSTR : 104.25 (+12.68%)
HL : 20.54 (+14.43%)
CDE : 20.93 (+13.07%)
GLXY : 21.90 (+7.20%)
TRI : 104.95 (+4.02%)
COIN : 160.20 (+9.55%)
STX : 832.56 (-7.87%)
WDC : 462.09 (-6.87%)
AMD : 466.42 (-3.71%)
SCCO : 194.68 (+3.66%)
^BTCUSD : 69,216.00 (+0.29%)
SPY : 769.06 (+0.21%)
Stocks Mixed on Lower Bond Yields and Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) is up by +0.33% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.33%. E-mini S&P futures...

AMAT : 496.17 (-3.53%)
B : 45.13 (+7.22%)
AVGO : 362.48 (-4.61%)
HL : 20.54 (+14.43%)
INTU : 362.47 (+3.44%)
SNDK : 1,568.87 (-3.50%)
CDE : 20.93 (+13.07%)
MRK : 152.20 (+12.60%)
TRI : 104.95 (+4.02%)
$IUXX : 29,426.02 (-0.22%)
ZNU26 : 108-260 (+0.03%)
ESU26 : 7,740.50 (+0.15%)
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma...

MRK : 152.20 (+12.60%)
MRNA : 174.38 (+176.97%)
S&P Futures Steady as Bonds Stabilize After Selloff, FOMC Minutes on Tap

September S&P 500 E-Mini futures (ESU26) are down -0.02% this morning, steadying after yesterday’s drop as the global bond rout eased, while investors await the release of the Federal Reserve’s July...

TGT : 159.00 (+4.28%)
TJX : 144.50 (-4.21%)
SNDK : 1,568.87 (-3.50%)
INTU : 362.47 (+3.44%)
ADI : 373.26 (-0.89%)
EL : 98.01 (+16.30%)
FN : 454.55 (-5.81%)
SKHY : 156.16 (+0.35%)
KLAR : 14.73 (-2.19%)
GEBN.Z.IX : 567.000 (+7.43%)
LOW : 220.00 (+2.02%)
FLS.C.DX : 526.000 (+5.79%)
Option Volatility And Earnings Report For Aug 17-21

It’s all about retail earnings this week with Walmart, Home Depot, Target and Alibaba all set to report.

TGT : 159.00 (+4.28%)
BABA : 128.90 (+0.59%)
NVDA : 217.56 (-0.99%)
TSLA : 351.12 (+4.23%)
NU : 14.61 (+1.81%)
NEM : 125.08 (+7.85%)
HD : 344.30 (+2.02%)
MRNA : 174.38 (+176.97%)
WMT : 114.30 (-0.78%)
Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

MRNA : 174.38 (+176.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 258.07
2nd Resistance Point 217.37
1st Resistance Point 195.87
Last Price 174.38
1st Support Level 133.67
2nd Support Level 92.97
3rd Support Level 71.47

See More

52-Week High 176.66
Last Price 174.38
Fibonacci 61.8% 117.69
Fibonacci 50% 99.47
Fibonacci 38.2% 81.25
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.